Aromatic l-amino acid decarboxylase (AADC) deficiency is an autosomal recessive disorder, caused by defects in the DDC gene. AADC catalyzes the synthesis of the neurotransmitters dopamine and serotonin from l-dopa and 5-HT respectively. Most patients are bed ridden for life, with little response to treatment. We now report one female patient who improved her motor and cognitive function after being prescribed a MAO-B inhibitor.
A five years old female presented with the typical clinical features of AADC deficiency. She was floppy, with no head control, had intermittent limb dystonia, and an upward deviation of the eyes (oculogyric crisis). This patient possessed compound heterozygous mutations in DDC (p.Trp105Cys, p.Pro129Ser), with a CSF draw indicating abnormal patterns of biogenic amine metabolites, compatible with AADC deficiency.
After her diagnosis at 3 years of age, medication with levodopa and vitamin B6 failed to show any efficacy. Subsequent administration with a MAO-B inhibitor improved her psychomotor functions to the extent that at 5 years of age she could walk several meters with support.
Our analyses of chemical findings, together with in silico structure predictions, lead us to hypothesize that this patient retained some AADC activity. In these cases, accurate diagnosis and early treatment should improve patient outcome.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Brain and Development
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Clinical and biochemical features of aromatic l-amino acid decarboxylase deficiency.Neurology. 2010; 75: 64-71
- The lumbar puncture for diagnosis of pediatric neurotransmitter diseases.Ann Neurol. 2003; 54: S13-S17
- Aromatic l-amino acid decarboxylase deficiency: overview of clinical features and outcomes.Ann Neurol. 2003; 54: S49-S55
- Unusually mild phenotype of AADC deficiency in 2 siblings.Mol Genet Metab. 2007; 91: 374-378
- Aromatic l-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis.Neurology. 2004; 62: 1058-1065
- Aromatic l-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up.J Inherit Metab Dis. 2009; 32: 371-380
- De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood.Nat Genet. 2013; 45: 445-449
- Variant of dihydropteridine reductase deficiency without hyperphenylalaninaemia: effect of oral phenylalanine loading.J Inherit Metab Dis. 1999; 22: 216-220
- Open conformation of human DOPA decarboxylase reveals the mechanism of PLP addition to Group II decarboxylases.Proc Natl Acad Sci U S A. 2011; 108: 20514-20519
- A comprehensive picture of the mutations associated with aromatic amino acid decarboxylase deficiency: from molecular mechanisms to therapy implications.Hum Mol Genet. 2014; 23: 5429-5440
Published online: June 29, 2016
Accepted: June 4, 2016
Received in revised form: May 22, 2016
Received: February 28, 2016
© 2016 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.